Pick one. You can't have both.
Obviously they didn't start from zero. But it wasn't like they had something from, say, 2018 that was looking promising but just hadn't made it all the way through trials yet. They had nothing but failures.
Their 10-K from the end of 2019: https://www.sec.gov/Archives/edgar/data/1682852/000168285220...
> We have a diverse pipeline of 24 development candidates, 12 of which are currently in clinical trials, and many of which have the potential to be first-in-class or best-in-class medicines.
All of this is a bit academic, anyways. We've plenty of evidence the Moderna vaccine works. You can quibble over the exact rate of rare side effects a little, but it's abundantly clear it's good at reducing deaths and severe disease in the vaccinated population.
The point discussed is not whether it works or not, but what are the actual safety parameters.
That's not a "Pfizer's is slightly safer in 30+ males and should be used preferentially in that population if both are available" safety quibble.
The expected vaccine sales were high enough to justify spending resources initiating developement on lots of candidate mRNA vaccines in parallel, and spending the money testing more of the potentially viable ones at a time than would otherwise have been the case. When you throw a lot more against the wall, you find something that sticks a lot faster.
If it's any old cave, you might just explore one at a time.
If you're pretty sure the Holy Grail is somewhere in it, you might hire six explorers, at higher initial expense.